245 related articles for article (PubMed ID: 21215696)
21. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in the pharmacogenetics of clopidogrel.
Cuisset T; Morange PE; Alessi MC
Hum Genet; 2012 May; 131(5):653-64. PubMed ID: 22207144
[TBL] [Abstract][Full Text] [Related]
23. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
[TBL] [Abstract][Full Text] [Related]
24. [Genetic variability in the efficacy of clopidogrel].
Kristensen KE; Rasmussen HB; Hansen PR
Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
[TBL] [Abstract][Full Text] [Related]
25. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
Luo Y; Zhao YT; Verdo A; Qi WG; Zhang DF; Hu B
J Int Med Res; 2011; 39(5):2012-9. PubMed ID: 22118006
[TBL] [Abstract][Full Text] [Related]
26. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Ichikawa M; Takei Y; Hamasaki T; Kijima Y
Circ J; 2015; 79(1):85-90. PubMed ID: 25744629
[TBL] [Abstract][Full Text] [Related]
27. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099
[TBL] [Abstract][Full Text] [Related]
28. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
Lee JM; Park S; Shin DJ; Choi D; Shim CY; Ko YG; Kim JS; Shin ES; Chang CW; Lee JE; Jang Y
Am J Cardiol; 2009 Jul; 104(1):46-51. PubMed ID: 19576320
[TBL] [Abstract][Full Text] [Related]
29. [CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
Galiavich AS; Valeeva DD; Minnetdinov RSh; Arkhipova AA; Akhmetov II; Galiavi RA
Kardiologiia; 2012; 52(4):20-4. PubMed ID: 22839512
[TBL] [Abstract][Full Text] [Related]
30. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
Angiolillo DJ; Ueno M
JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
[No Abstract] [Full Text] [Related]
31. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.
Oh IY; Park KW; Kang SH; Park JJ; Na SH; Kang HJ; Koo BK; Jeong YH; Hwang JY; Kwak CH; Park Y; Hwang SJ; Ko YG; Shin DJ; Jang Y; Kim HS
Heart; 2012 Jan; 98(2):139-44. PubMed ID: 21700758
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.
Lee JB; Lee KA; Lee KY
Yonsei Med J; 2011 Sep; 52(5):734-8. PubMed ID: 21786436
[TBL] [Abstract][Full Text] [Related]
33. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
[TBL] [Abstract][Full Text] [Related]
34. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
35. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
Xie X; Ma YT; Yang YN; Li XM; Ma X; Fu ZY; Zheng YY; Chen BD; Liu F
PLoS One; 2013; 8(3):e59344. PubMed ID: 23555019
[TBL] [Abstract][Full Text] [Related]
36. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
Tang XF; He C; Yuan JQ; Meng XM; Yang YJ; Qin XW; Qiao SB; Liu HB; Wu YJ; Yao M; Chen J; You SJ; Wu Y; Li JJ; Dai J; Chen JL; Gao RL; Chen ZJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):617-20. PubMed ID: 22088240
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
Sibbing D; Stegherr J; Latz W; Koch W; Mehilli J; Dörrler K; Morath T; Schömig A; Kastrati A; von Beckerath N
Eur Heart J; 2009 Apr; 30(8):916-22. PubMed ID: 19193675
[TBL] [Abstract][Full Text] [Related]
38. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
[TBL] [Abstract][Full Text] [Related]
39. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
Gurbel PA; Tantry US; Shuldiner AR
JACC Cardiovasc Interv; 2009 Nov; 2(11):1102-4. PubMed ID: 19926051
[No Abstract] [Full Text] [Related]
40. Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
Kleiman NS
JACC Cardiovasc Interv; 2008 Dec; 1(6):628-30. PubMed ID: 19463376
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
